title: Antiproliferative, Ultrastructural, and Physiological Effects of Amiodarone on Promastigote and Amastigote Forms of Leishmania amazonensis.
abstract: Amiodarone (AMIO), the most frequently antiarrhythmic drug used for the symptomatic treatment of chronic Chagas' disease patients with cardiac compromise, has recently been shown to have also specific activity against fungi, Trypanosoma cruzi and Leishmania. In this work, we characterized the effects of AMIO on proliferation, mitochondrial physiology, and ultrastructure of Leishmania amazonensis promastigotes and intracellular amastigotes. The IC(50) values were 4.21 and 0.46 μM against promastigotes and intracellular amastigotes, respectively, indicating high selectivity for the clinically relevant stage. We also found that treatment with AMIO leads to a collapse of the mitochondrial membrane potential (ΔΨm) and to an increase in the production of reactive oxygen species, in a dose-dependent manner. Fluorescence microscopy of cells labeled with JC-1, a marker for mitochondrial energization, and transmission electron microscopy confirmed severe alterations of the mitochondrion, including intense swelling and modification of its membranes. Other ultrastructural alterations included (1) presence of numerous lipid-storage bodies, (2) presence of large autophagosomes containing part of the cytoplasm and membrane profiles, sometimes in close association with the mitochondrion and endoplasmic reticulum, and (3) alterations in the chromatin condensation and plasma membrane integrity. Taken together, our results indicate that AMIO is a potent inhibitor of L. amazonensis growth, acting through irreversible alterations in the mitochondrial structure and function, which lead to cell death by necrosis, apoptosis and/or autophagy.
authors.affiliation: Laboratório de Ultraestrutura Celular Hertha Meyer, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Avenida Carlos Chagas, 373, CCS, Ilha do Fundão, 21941-902 Rio de Janeiro, Brazil.
authors.forename: Sara Teixeira
authors.initials: ST
authors.lastname: de Macedo-Silva
authors.forename: Thais Larissa Araújo
authors.initials: TL
authors.lastname: de Oliveira Silva
authors.forename: Julio A
authors.initials: JA
authors.lastname: Urbina
authors.forename: Wanderley
authors.initials: W
authors.lastname: de Souza
authors.forename: Juliany Cola Fernandes
authors.initials: JC
authors.lastname: Rodrigues
references.citation: Antimicrob Agents Chemother. 2009 Dec;53(12):5108-13
references.pmid: 19805563
references.citation: Protist. 2007 Oct;158(4):447-56
references.pmid: 17719843
references.citation: J Biol Chem. 2003 Aug 1;278(31):28831-9
references.pmid: 12754197
references.citation: J Med Chem. 2003 Oct 23;46(22):4714-27
references.pmid: 14561091
references.citation: J Biol Chem. 2004 Dec 10;279(50):52366-75
references.pmid: 15355995
references.citation: Vet Parasitol. 2007 May 15;146(1-2):25-34
references.pmid: 17367936
references.citation: J Med Chem. 2006 Feb 9;49(3):892-9
references.pmid: 16451055
references.citation: Arzneimittelforschung. 1993 Jul;43(7):782-3
references.pmid: 8369013
references.citation: Med Microbiol Immunol. 2004 Nov;193(4):173-80
references.pmid: 14513375
references.citation: Clin Microbiol Rev. 2006 Jan;19(1):111-26
references.pmid: 16418526
references.citation: Interdiscip Perspect Infect Dis. 2009;2009:642502
references.pmid: 19680554
references.citation: Toxicol Lett. 1998 Sep 1;98(1-2):41-50
references.pmid: 9776560
references.citation: Ther Clin Risk Manag. 2008 Jun;4(3):659-63
references.pmid: 18827865
references.citation: Int J Cardiol. 2006 Jun 7;110(1):27-32
references.pmid: 16046015
references.citation: Mol Pharmacol. 2008 Nov;74(5):1292-307
references.pmid: 18703668
references.citation: J Pharmacol Exp Ther. 2002 Jan;300(1):195-9
references.pmid: 11752116
references.citation: Cell Biochem Funct. 1997 Sep;15(3):145-52
references.pmid: 9377792
references.citation: J Cell Biol. 2005 Jan 17;168(2):257-69
references.pmid: 15657396
references.citation: Eur J Pharmacol. 1993 Sep 28;242(2):113-8
references.pmid: 8253107
references.citation: Antimicrob Agents Chemother. 2009 Apr;53(4):1403-10
references.pmid: 19164149
references.citation: J Eukaryot Microbiol. 1995 Jul-Aug;42(4):337-46
references.pmid: 7620457
references.citation: Cell Death Differ. 2004 Aug;11(8):924-36
references.pmid: 15118764
references.citation: FEMS Microbiol Lett. 2006 Feb;255(1):33-42
references.pmid: 16436059
references.citation: Chemotherapy. 2009;55(4):228-33
references.pmid: 19451712
references.citation: Antimicrob Agents Chemother. 2002 Feb;46(2):487-99
references.pmid: 11796362
references.citation: J Parasitol. 1960 Oct;46:529-39
references.pmid: 13783227
references.citation: Biochem Pharmacol. 2003 Apr 1;65(7):1115-28
references.pmid: 12663047
references.citation: J Eukaryot Microbiol. 2001 Sep-Oct;48(5):588-94
references.pmid: 11596924
references.citation: Comp Immunol Microbiol Infect Dis. 2004 Sep;27(5):305-18
references.pmid: 15225981
references.citation: Int J Antimicrob Agents. 1996 Oct;7(4):235-40
references.pmid: 18611761
references.citation: Antimicrob Agents Chemother. 2004 Aug;48(8):2937-50
references.pmid: 15273104
references.citation: Antimicrob Agents Chemother. 2008 Nov;52(11):4098-114
references.pmid: 18765694
references.citation: Trends Parasitol. 2005 Nov;21(11):508-12
references.pmid: 16150644
references.citation: Lancet Infect Dis. 2010 Mar;10(3):184-94
references.pmid: 20185097
references.citation: Exp Toxicol Pathol. 2012 Jul;64(5):425-30
references.pmid: 21093234
references.citation: Mol Microbiol. 2003 Jan;47(1):223-34
references.pmid: 12492866
references.citation: Curr Pharm Des. 2008;14(9):925-38
references.pmid: 18473841